Sandesh Mahatme - 05 Dec 2025 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Role: CFO
Signature: Adi Osovsky, Attorney-in-Fact
Issuer symbol: VOR
Transactions as of: 05 Dec 2025
Transactions value $: $0
Form type: 4
Filing time: 09 Dec 2025, 08:00:10 UTC
Previous filing: 10 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Mahatme Sandesh	CFO	C/O VOR BIOPHARMA INC., 500 BOYLSTON STREET, SUITE 1350, BOSTON	Adi Osovsky, Attorney-in-Fact	09 Dec 2025	0001511034

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VOR	Common Stock	Disposed to Issuer	$0	-694K	-100%	$0.00	0	05 Dec 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VOR	Employee Stock Option (right to buy)	Award	$0	+1.39M		$0.00	1.39M	05 Dec 2025	Common Stock	1.39M	$17.80	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The share counts herein reflect the reverse stock split.
F2	On December 5, 2025, the Issuer's Compensation Committee of the Board of Directors approved the cancellation of the previously awarded grant of 694,137 restricted stock units, which was reported in a Form 4 filed on July 10, 2025.
F3	The exercise price per share of common stock subject to the option will be (a) $17.80 per share, or (b) to the extent the option is exercised following the end of the Retention Period, $8.18 per share, the closing price of a share of common stock on the grant date (December 5, 2025). The "Retention Period" begins on December 5, 2025 and ends on the earlier of (i) December 5, 2027 or (ii) a Change in Control (as defined in the 2021 Plan) during the Reporting Person's Continuous Service (as defined in the 2021 Plan) with the Issuer. In the event that the Reporting Person's Continuous Service terminates for any reason or no reason prior to the end of the Retention Period, the exercise price per share of Common Stock subject to the Option will be as set forth in clause (a) above.
F4	1/4th of the shares underlying the option vest on July 1, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.